INTENSIVIST Volume 11, Issue 1 (January 2019)
Japanese

Tigecycline use in critical care setting Hiroki SAITO 1 , Koh OKAMOTO 2 1Department of Emergency and Critical Care Medicine St. Marianna University School of Medicine Yokohama City Seibu Hospital 2Deparment of Infectious Diseases The University of Tokyo Hospital pp.32-35
Published Date 2019/1/1
DOI https://doi.org/10.11477/mf.3102200594
  • Abstract
  • Look Inside
  • Reference

Tigecycline, a derivative of the tetracyclines, can be a good treatment option for patients with infections due to multi-drug resistant organisms and severe infections in the critical care setting. It covers a broad spectrum of organisms, particularly gram-negative organisms except Pseudomonas, and can be even used as part of combination therapy for infections by carbapenem resistant organisms such as complicated intra-abdominal infections. Although it does not require renal dose adjustment and its use is relatively simple, the risk-benefit balance needs to be considered given the available evidence of potentially higher mortality with tigecycline. Further research is required to define the clinical indications and utility in the era of antimicrobial resistance.


Copyright © 2019, MEDICAL SCIENCES INTERNATIONAL, LTD. All rights reserved.

基本情報

18834833.11.1.jpg
INTENSIVIST
11巻1号 (2019年1月)
電子版ISSN 2186-7852 印刷版ISSN 1883-4833 メディカル・サイエンス・インターナショナル

関連文献

もっと見る

文献を共有